Published in Expert Rev Clin Immunol on January 01, 2008
Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann Neurol (2009) 1.01
Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment? Ann N Y Acad Sci (2008) 0.92
Applying complement therapeutics to rare diseases. Clin Immunol (2015) 0.87
Cell surface complement regulators moderate experimental myasthenia gravis pathology. Muscle Nerve (2012) 0.83
Biomarker development for myasthenia gravis. Ann N Y Acad Sci (2012) 0.78
Targeting therapy to the neuromuscular junction: proof of concept. Muscle Nerve (2014) 0.76
Viral-derived complement inhibitors: current status and potential role in immunomodulation. Exp Biol Med (Maywood) (2016) 0.75
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med (2006) 5.26
Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science (2007) 4.52
Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology (2000) 4.17
A second serine protease associated with mannan-binding lectin that activates complement. Nature (1997) 3.64
Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med (2001) 3.26
Myasthenia gravis: past, present, and future. J Clin Invest (2006) 3.06
Myasthenia gravis. Lancet (2001) 2.82
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology (1990) 2.77
Molecular cloning and chromosomal localization of human membrane cofactor protein (MCP). Evidence for inclusion in the multigene family of complement-regulatory proteins. J Exp Med (1988) 2.75
Decay-accelerating factor modulates induction of T cell immunity. J Exp Med (2005) 2.34
T-cell regulation: with complements from innate immunity. Nat Rev Immunol (2006) 2.27
Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med (1978) 2.15
The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med (2005) 2.09
Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol (2004) 1.89
Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc (1977) 1.85
Extraocular muscle is defined by a fundamentally distinct gene expression profile. Proc Natl Acad Sci U S A (2001) 1.71
Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 1. Relation to clinical parameters in 250 patients. J Neurol Sci (1983) 1.69
The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol (2004) 1.65
Acetylcholine receptors and myasthenia. Muscle Nerve (2000) 1.61
Fc receptors and their interaction with complement in autoimmunity. Immunol Lett (2005) 1.60
The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. J Exp Med (1987) 1.55
Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med (1978) 1.51
Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol (2001) 1.41
Complement: central to innate immunity and bridging to adaptive responses. Immunol Lett (2004) 1.36
Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol (1980) 1.35
Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol (2003) 1.32
Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest (2002) 1.31
Holding T cells in check--a new role for complement regulators? Trends Immunol (2006) 1.30
The complement system in B cell regulation. Mol Immunol (2004) 1.28
Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J Neuroimmunol (1996) 1.21
Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol (2005) 1.20
Targeting complement in therapy. Immunol Rev (2001) 1.16
Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol (2005) 1.14
Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest (2006) 1.13
Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J Immunol (1989) 1.12
The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin Exp Immunol (2006) 1.12
Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J Neuroimmunol (2006) 1.09
The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6, and monocyte chemoattractant peptide-1 by human umbilical vein endothelial cells. J Immunol (1998) 1.07
Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci (1987) 1.06
Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia. Proc Natl Acad Sci U S A (1983) 1.06
Self, non-self, and danger: a complementary view. Adv Exp Med Biol (2006) 1.05
Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia. Exp Neurol (2006) 1.05
C5 gene influences the development of murine myasthenia gravis. J Immunol (1988) 1.05
Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol (2007) 1.05
Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J Immunol (2003) 1.04
Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Exp Neurol (2004) 1.04
Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology (1993) 1.03
Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J Immunol (2002) 0.99
Antigenic modulation and receptor loss in experimental autoimmune myasthenia gravis. Muscle Nerve (1980) 0.99
B cell targeted therapy in autoimmunity. J Autoimmun (2007) 0.99
Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. J Immunol (2005) 0.98
Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol (2007) 0.97
Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia. Arch Neurol (2000) 0.96
Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures. J Neuroimmunol (2007) 0.96
Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice. J Immunol (2000) 0.95
Titin antibodies in patients with late onset myasthenia gravis: clinical correlations. Autoimmunity (1995) 0.91
Expression of CD59, a regulator of the membrane attack complex of complement, on human skeletal muscle fibers. Muscle Nerve (1997) 0.89
Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin Exp Immunol (2006) 0.89
Production of interleukin (IL)-5 and IL-10 accompanies T helper cell type 1 (Th1) cytokine responses to a major thyroid self-antigen, thyroglobulin, in health and autoimmune thyroid disease. Clin Exp Immunol (2007) 0.89
IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1. J Immunol (2005) 0.89
Scenarios for autoimmunization of T and B cells in myasthenia gravis. Ann N Y Acad Sci (2003) 0.88
Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: A model agent for long-term complement inhibition in vivo. Mol Immunol (2007) 0.88
Anti-TNF-alpha antibodies suppress the development of experimental autoimmune myasthenia gravis. J Autoimmun (2002) 0.87
Absence of IL-4 facilitates the development of chronic autoimmune myasthenia gravis in C57BL/6 mice. J Immunol (2003) 0.87
The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo. J Neuroimmunol (2005) 0.86
Role of complement in inflammation and injury in the nervous system. Exp Clin Immunogenet (1997) 0.85
Ocular myasthenia: diagnosis, treatment, and pathogenesis. Neurologist (2006) 0.85
Role of complement in the development of autoimmunity. Curr Dir Autoimmun (2003) 0.85
Complement regulatory proteins and selective vulnerability of neurons to lysis on exposure to acetylcholinesterase antibody. J Neuroimmunol (2001) 0.85
Tumor necrosis factor-alpha, lymphotoxin, interleukin (IL)-6, IL-10, IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis. J Neuroimmunol (1996) 0.85
Genetic evidence for the involvement of Fcgamma receptor III in experimental autoimmune myasthenia gravis pathogenesis. J Neuroimmunol (2006) 0.83
A triple antibody assay for the quantitation of plasma IgG subclass antibodies to acetylcholine receptors in patients with myasthenia gravis. J Immunol Methods (1985) 0.83
Antibodies in sera from patients with myasthenia gravis do not bind to nicotinic acetylcholine receptors from human brain. J Neuroimmunol (1987) 0.83
A molecular basis of activation of the alternative pathway of human complement. Adv Exp Med Biol (1979) 0.82
S-protein is expressed in necrotic fibers in Duchenne muscular dystrophy and polymyositis. Muscle Nerve (2003) 0.81
Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis. J Neuroimmunol (2006) 0.81
Complement component C1 and the collectins--first-line defense molecules in innate and acquired immunity. Trends Immunol (2002) 0.79
Soluble terminal complement components in human myasthenia gravis. Clin Neurol Neurosurg (1993) 0.79
Complement and immunity. Rheum Dis Clin North Am (2004) 0.78
Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. A study of IgG subclasses and clinical correlations. J Neuroimmunol (2000) 0.78
Pros and cons of treating murine myasthenia gravis with anti-C1q antibody. J Neuroimmunol (2006) 0.78
Complement enhances the clearance of large-sized soluble IgA aggregates in rats. Eur J Immunol (1991) 0.78
Complementary therapies for inflammation. Nat Biotechnol (2006) 0.77
In vitro modulation of C1q mRNA expression and secretion by interleukin-1, interleukin-6, and interferon-gamma in resident and stimulated murine peritoneal macrophages. Immunobiology (2002) 0.77
Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis. Neuromuscul Disord (2006) 0.77
Circulating immune complexes augment severity of antibody-mediated myasthenia gravis in hypogammaglobulinemic RIIIS/J mice. J Immunol (2004) 0.76
X-linked vacuolated myopathy: membrane attack complex deposition on the surface membrane of injured muscle fibers is not accompanied by S-protein. Muscle Nerve (1998) 0.76
[Pathophysiological characterization of congenital myasthenic syndromes: the example of mutations in the MUSK gene]. J Soc Biol (2005) 0.76
Supply and demand analysis of the current and future US neurology workforce. Neurology (2013) 4.52
Myasthenia gravis: past, present, and future. J Clin Invest (2006) 3.06
A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet (2002) 2.80
Recommendations for myasthenia gravis clinical trials. Muscle Nerve (2012) 2.28
Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol (2010) 1.46
Practice parameters and focusing research: plasma exchange for myasthenia gravis. Muscle Nerve (2011) 1.41
Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest (2002) 1.31
Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice. J Neurol Sci (2007) 1.31
Temporal and spatial mRNA expression patterns of TGF-beta1, 2, 3 and TbetaRI, II, III in skeletal muscles of mdx mice. Neuromuscul Disord (2005) 1.27
A genetic model for muscle-eye-brain disease in mice lacking protein O-mannose 1,2-N-acetylglucosaminyltransferase (POMGnT1). Mech Dev (2006) 1.23
Ocular myasthenia revisited: insights from pseudo-internuclear ophthalmoplegia. J Neurol (2007) 1.20
Persistent over-expression of specific CC class chemokines correlates with macrophage and T-cell recruitment in mdx skeletal muscle. Neuromuscul Disord (2003) 1.19
Molecular architecture of the neuromuscular junction. Muscle Nerve (2006) 1.16
Myosin heavy chain expression in mouse extraocular muscle: more complex than expected. Invest Ophthalmol Vis Sci (2010) 1.09
Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone. Ann N Y Acad Sci (2008) 1.08
Pitx2, an atrial fibrillation predisposition gene, directly regulates ion transport and intercalated disc genes. Circ Cardiovasc Genet (2014) 1.07
Treatment of myasthenia gravis. Curr Neurol Neurosci Rep (2011) 1.02
The MGTX experience: challenges in planning and executing an international, multicenter clinical trial. J Neuroimmunol (2008) 1.02
Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann Neurol (2009) 1.01
Pathophysiology of myasthenia gravis. Semin Neurol (2004) 1.00
Constitutive properties, not molecular adaptations, mediate extraocular muscle sparing in dystrophic mdx mice. FASEB J (2003) 1.00
An altered phenotype in a conditional knockout of Pitx2 in extraocular muscle. Invest Ophthalmol Vis Sci (2009) 0.99
Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2007) 0.99
Distinctive morphological and gene/protein expression signatures during myogenesis in novel cell lines from extraocular and hindlimb muscle. Physiol Genomics (2005) 0.98
Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol (2007) 0.97
Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy. Ann N Y Acad Sci (2003) 0.96
Role of IL-10 deficiency in excessive nuclear factor-kappaB activation and lung inflammation in cystic fibrosis transmembrane conductance regulator knockout mice. J Allergy Clin Immunol (2005) 0.93
Acute Pseudomonas challenge in cystic fibrosis mice causes prolonged nuclear factor-kappa B activation, cytokine secretion, and persistent lung inflammation. J Allergy Clin Immunol (2006) 0.92
Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment? Ann N Y Acad Sci (2008) 0.92
Perimysial fibroblasts of extraocular muscle, as unique as the muscle fibers. Invest Ophthalmol Vis Sci (2009) 0.92
Neuromuscular manifestations of endocrine disorders. Neurol Clin (2002) 0.89
Implementing clinical trials on an international platform: challenges and perspectives. J Neurol Sci (2011) 0.89
Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr Opin Neurol (2008) 0.86
Ocular myasthenia: diagnosis, treatment, and pathogenesis. Neurologist (2006) 0.85
Molecular organization of the extraocular muscle neuromuscular junction: partial conservation of and divergence from the skeletal muscle prototype. Invest Ophthalmol Vis Sci (2003) 0.85
Pitx2 regulates myosin heavy chain isoform expression and multi-innervation in extraocular muscle. J Physiol (2011) 0.84
Cell surface complement regulators moderate experimental myasthenia gravis pathology. Muscle Nerve (2012) 0.83
The role of Rac2 in regulating neutrophil production in the bone marrow and circulating neutrophil counts. Am J Pathol (2008) 0.82
Mexiletine for treatment of myotonia: a trial triumph for rare disease networks. JAMA (2012) 0.80
Electrodiagnostic approach to the patient with suspected neuromuscular junction disorder. Neurol Clin (2002) 0.79
Genomic profiling reveals Pitx2 controls expression of mature extraocular muscle contraction-related genes. Invest Ophthalmol Vis Sci (2012) 0.78
Adverse effects of myasthenia gravis on rat phrenic diaphragm contractile performance. J Appl Physiol (1985) (2004) 0.78
The role of complement in experimental autoimmune myasthenia gravis. Ann N Y Acad Sci (2012) 0.77
Epstein-Barr virus: Trigger for autoimmunity? Ann Neurol (2010) 0.77
Preoperative preparation of patients with myasthenia gravis forestalls postoperative respiratory complications after thymectomy. Ann Thorac Surg (2003) 0.77
Targeting therapy to the neuromuscular junction: proof of concept. Muscle Nerve (2014) 0.76
Monocular visual deprivation in macaque monkeys: a profile in the gene expression of lateral geniculate nucleus by laser capture microdissection. Mol Vis (2008) 0.76
Author response. Neurology (2015) 0.75
Importance and hurdles to drug discovery for neurological disease. Ann Neurol (2013) 0.75
Restoring balance at the neuromuscular junction. Neurology (2007) 0.75
Thymectomy for myasthenia gravis: evaluation requires controlled prospective studies. Ann Thorac Surg (2003) 0.75
Concurrent Paraspinous Myopathy and Myasthenia Gravis. J Clin Neuromuscul Dis (2017) 0.75
Outcome of plasmapheresis in myasthenia gravis: delayed therapy is not favorable. Muscle Nerve (2011) 0.75
Two steps forward, one step back: mycophenolate mofetil treatment for myasthenia gravis in the United States. Muscle Nerve (2015) 0.75
Problems in the evaluation of thymectomy for myasthenia gravis. Ann Thorac Surg (2002) 0.75